GLASSIA

Adults with emphysema who have significant alpha-antitrypsin insufficiency may benefit from long-term augmentation and maintenance therapy with GLASSIA® (Alpha-Proteinase Inhibitor [Human]). Accurate reimbursement and compliance depend on proper billing and coding. Here are several important rules:
HCPCS Code: J0257: Human alpha 1-proteinase inhibitor injection (10 mg), GLASSIA.
Billing Example: Since each unit represents 10 mg, bill 100 units for a 1,000 mg dose of GLASSIA.

00944-2884-01: GLASSIA 1 g/50 mL intravenous solution is the National Drug Code (NDC).
Diagnosis Code: Alpha-1-antitrypsin deficiency (ICD-10-CM Code: E88.01).
Administration Considerations: GLASSIA is given intravenously and, with the right training, can be self-administered by the patient or caregiver or delivered by a medical expert.

Additional Billing Considerations: Modifiers: Modifiers like JW (drug quantity discarded/not administered) may be relevant depending on payer restrictions and the particulars of the administration.
Documentation: To prove medical necessity and speed up the processing of claims, keep comprehensive medical records that include the diagnosis, treatment plan, dosage, administration method, and any information on waste.
Consult the manufacturer's GLASSIA Billing and Coding Guide for complete and current information.